C-VISA BikDD: Liposome in Advanced Pancreatic Cancer

Summary

The goal of this clinical research study is to find the highest tolerable dose of BikDD nanoparticle that can be given to patients with advanced cancer of the pancreas. The safety of this drug will also be studied.

Timeline

Start

2015-03

Primary completion

2017-03

Completion

2017-03

Outcome

Outcome not reported

Stopped: “Stability of the DNA when admixed with the liposome failed”

Drugs

Indications